Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Tuberculosis In Sub-Saharan Africa: Opportunities, Challenges, And Change In The Era Of Antiretroviral Treatment

E. Corbett, B. Marston, G. Churchyard, K. M. Cock
Published 2006 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Rapid scale-up of antiretroviral treatment programmes is happening in Africa, driven by international advocacy and policy directives and supported by unprecedented donor funding and technical assistance. This welcome development offers hope to millions of HIV-infected Africans, among whom tuberculosis is the major cause of serious illness and death. Little in the way of HIV diagnosis or care was previously offered to patients with tuberculosis, by either national tuberculosis or AIDS control programmes, with tuberculosis services focused exclusively on diagnosis and treatment of rising numbers of patients. Tuberculosis control in Africa has yet to adapt to the new climate of antiretroviral availability. Many barriers exist, from drug interactions to historic differences in the way that tuberculosis and HIV are perceived, but failure to successfully integrate HIV and tuberculosis control will threaten the viability of both programmes. Here, we review tuberculosis epidemiology in Africa and policy implications of HIV/AIDS treatment scale-up.
This paper references
10.1542/peds.2006-2052
Trends in Opportunistic Infections in the Pre–and Post–Highly Active Antiretroviral Therapy Eras Among HIV-Infected Children in the Perinatal AIDS Collaborative Transmission Study, 1986–2004
S. Nesheim (2007)
10.1016/J.JHEP.2005.01.022
Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol.
D. Salmon-Céron (2005)
10.1097/00004836-198109000-00012
Risk factors for isoniazid (NIH)-induced liver dysfunction.
D. Dickinson (1981)
10.1097/00002030-199312000-00005
The mortality and pathology of HIV infection in a West African city
S. Lucas (1993)
10.1164/AJRCCM.157.6.9711039
Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus.
J. Ungo (1998)
HIV infection and silicosis: the impact of two potent risk factors on mycobacterial disease incidence in South African miners
EL Corbett (2000)
10.1097/00002030-200111090-00009
Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults
J. Johnson (2001)
10.1097/00002030-200501280-00008
Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa
K. Grimwade (2005)
10.1126/SCIENCE.1086845
Antiretroviral Drugs for Tuberculosis Control in the Era of HIV/AIDS
B. Williams (2003)
10.1016/j.trstmh.2008.06.010
Provision of antiretroviral therapy to children within the public sector of South Africa.
P. Bock (2008)
10.1097/00002030-199511000-00006
Autopsy‐proven causes of death in HIV‐infected patients treated for tuberculosis in Abidjan, Côte d'lvoire
A. Greenberg (1995)
10.1164/AJRCCM/147.4.958
Quantitative bacillary response to treatment in HIV-associated pulmonary tuberculosis.
R. Brindle (1993)
Design of regimens for treating tuberculosis in patients with HIV infection, with particular reference to sub-Saharan Africa.
A. Harries (2001)
10.1056/nejm199902043400507
Tuberculosis in patients with human immunodeficiency virus infection.
D. Havlir (1999)
[Condom effectiveness in reducing heterosexual HIV transmission].
E. Smith (2002)
Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998.
N. Ansari (2002)
A review of the diagnosis and treatment of smear-negative pulmonary tuberculosis.
R. Colebunders (2000)
Should the 'bleach microscopy method' be recommended for improved case detection of tuberculosis? Literature review and key person analysis.
K. Angeby (2004)
10.1086/515221
Isoniazid toxicity in health care workers.
R. Stuart (1999)
Prevention of mother-to-child transmission of human immunodeficiency virus among pregnant women using injecting drugs
C Thorne (2000)
The impact of the HIV epidemic on pulmonary tuberculosis in Karonga district, Malawi: analyses of the evolving relative risk of tuberculosis associated with HIV infection
E Vynnycky (2004)
10.1097/00002030-200101260-00002
Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa
Y. Mukadi (2001)
10.1097/00002030-200311210-00013
Tuberculosis epidemics driven by HIV
C. Currie (2003)
10.1097/01.aids.0000176211.08581.5a
How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control
S. Lawn (2005)
10.1080/09540120701687067
Patterns of care in two HIV continuity clinics in Uganda, Africa: a time-motion study
M. Were (2008)
What causes smear-negative pulmonary tuberculosis in Malawi, an area of high HIV seroprevalence?
N. Hargreaves (2001)
10.1016/S0140-6736(00)02730-6
Tuberculosis control and molecular epidemiology in a South African gold-mining community
P. Godfrey-Faussett (2000)
10.1097/00006454-200012000-00005
Adherence to medication regimens among children with human immunodeficiency virus infection
C. Reddington (2000)
10.1097/QAI.0b013e318032bbee
Antiretroviral-Associated Toxicity Among HIV-1-Seropositive Pregnant Women in Mozambique Receiving Nevirapine-Based Regimens
L. Jamisse (2007)
10.1371/journal.pmed.0030238
Uptake of Workplace HIV Counselling and Testing: A Cluster-Randomised Trial in Zimbabwe
E. Corbett (2006)
Population based screening for active tuberculosis in a community with endemic TB . 33 rd World Conference on Lung Health , 2002 , Montreal , Canada
GJ Churchyard (2005)
10.1056/NEJM199803053381001
An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis.
S. Valway (1998)
10.2165/00003088-200241140-00001
Antiretroviral Pharmacokinetics in the Paediatric Population
J. King (2002)
Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection.
K. Lyseng-Williamson (2005)
Human resources for health : overcoming the crisis
Joint Learning Initiative (2004)
Tuberculosis Chemotherapy Centre . The prevention and treatment of isoniazid toxicity in the therapy of pulmonary tuberculosis
Snider (1963)
10.1128/AAC.00461-06
Effect of Rifampin on Steady-State Pharmacokinetics of Atazanavir with Ritonavir in Healthy Volunteers
D. Burger (2006)
Tuberculosis deaths in countries with high HIV prevalence: what is their use as an indicator in tuberculosis programme monitoring and epidemiological surveillance?
D. Maher (2005)
10.1111/J.1728-4457.2007.00182.X
Sero‐Discordant Couples in Five African Countries: Implications for Prevention Strategies
D. Walque (2007)
10.1086/338641
Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy.
G. Santoro-Lopes (2002)
10.1016/S0140-6736(04)16597-5
Scaling up access to antiretroviral treatment in southern Africa: who will do the job?
K. Kober (2004)
A decline in community viral load in Cape Town and Johannesburg, South Africa
S Carmona (2004)
10.1128/AAC.00341-07
Effect of Concomitantly Administered Rifampin on the Pharmacokinetics and Safety of Atazanavir Administered Twice Daily
E. Acosta (2007)
10.1038/82139
Latent Mycobacterium tuberculosis–persistence, patience, and winning by waiting
Y. Manabe (2000)
10.1093/AJE/KWG036
When to initiate highly active antiretroviral therapy: a cohort approach.
Linda Ahdieh-Grant (2003)
10.1016/S0140-6736(04)17482-5
Human resources for health: overcoming the crisis
L. Chen (2004)
10.1136/thorax.57.9.810
A national study of clinical and laboratory factors affecting the survival of patients with multiple drug resistant tuberculosis in the UK
F. Drobniewski (2002)
10.1086/323896
Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis.
P. Sadaphal (2001)
10.1164/AJRCCM.156.4.9609143
Chest radiographic findings in patients with tuberculosis with recent or remote infection.
B. Jones (1997)
A comparison of direct microscopy, the concentration method and the Mycobacteria Growth Indicator Tube for the examination of sputum for acid-fast bacilli.
L. Apers (2003)
10.1080/09540120701335196
A model of integrated primary care for HIV-positive patients with underlying substance use and mental illness
N. Zaller (2007)
10.1086/421407
Utility of tuberculosis directly observed therapy programs as sites for access to and provision of antiretroviral therapy in resource-limited countries.
G. Friedland (2004)
Acceptance and safety of directly observed versus self-administered isoniazid preventive therapy in aboriginal peoples in British Columbia.
G. Heal (1998)
How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?
G. Comstock (1999)
From the Food and Drug Administration.
J. Samet (2002)
10.4314/THRB.V10I2.14350
Validation of self-report and hospital pill count using unannounced home pill count as methods for determination of adherence to antiretroviral therapy.
O. Minzi (2008)
Impact of human immunodeficiency virus type-1 infection on the initial bacteriologic and radiographic manifestations of pulmonary tuberculosis in Uganda
J. L. Johnson (1998)
HIV-related tuberculosis: how well are we doing with current control efforts?
D. Maher (2005)
10.7326/0003-4819-71-6-1113
Serum transaminase elevations and other hepatic abnormalities in patients receiving isoniazid.
L. Scharer (1969)
10.1001/ARCHINTE.162.3.355
Periconceptional exposure to efavirenz and neural tube defects.
M. De Santis (2002)
10.1097/QAI.0b013e31817bbc21
Efavirenz in Human Breast Milk, Mothers', and Newborns' Plasma
S. Schneider (2008)
10.1097/QAD.0b013e32830e6d51
Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis
H. Thein (2008)
10.1016/S0140-6736(99)03465-0
Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial
S. Wiktor (1999)
10.1001/jama.284.13.1641
Missed opportunities for prevention of tuberculosis among persons with HIV infection--selected locations, United States, 1996-1997.
(2000)
10.1016/0962-8479(92)90087-Z
Cohort study of HIV-positive and HIV-negative tuberculosis, Nairobi, Kenya: comparison of bacteriological results.
W. Githui (1992)
10.1016/S0140-6736(02)08830-X
Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru
P. Suarez (2002)
10.1016/0962-8479(94)91041-3
Acute respiratory infections (A. R. I.) in an outlying health formation: Epidemiology and cares
A. Andrianarisoa (1994)
10.1097/00007611-200295040-00009
Treatment of Latent Tuberculosis Infection in Contacts of New Tuberculosis Cases in the United States
M. Reichler (2002)
10.1111/j.1468-1293.2007.00477.x
Nevirapine‐associated toxicity in HIV‐infected Thai men and women, including pregnant women
N. Phanuphak (2007)
10.1016/j.trstmh.2008.04.002
Reasons for loss to follow-up among mothers registered in a prevention-of-mother-to-child transmission program in rural Malawi.
L. D. Bwirire (2008)
10.1016/0041-3879(80)90038-0
Pyridoxine supplementation during isoniazid therapy.
D. Snider (1980)
Comparison of two versus three smears in identifying culture-positive tuberculosis patients in a rural African setting with high HIV prevalence.
A. Crampin (2001)
GUIDELINES FOR THE PREVENTION OF TUBERCULOSIS IN HEALTH CARE FACILITIES IN RESOURCE-LIMITED SETTINGS
R. Granich (1999)
10.1001/ARCHINTE.166.15.1632
Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.
R. Weber (2006)
10.1097/00002030-200403260-00007
Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine
J. Macías (2004)
10.1097/00042560-200112150-00007
Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis.
E. Ribera (2001)
Assessing the impact of HIV on the annual risk of TB infection using a mathematical model
C. Currie (2005)
10.1136/adc.78.2.169
Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis
L. Ormerod (1998)
'Smear-negative' pulmonary tuberculosis in a DOTS programme: poor outcomes in an area of high HIV seroprevalence.
N. Hargreaves (2001)
10.1016/S0140-6736(02)09742-8
Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial
The Tuberculosis Trials Consortium (2002)
10.1097/00126334-200209010-00011
The Evolving Epidemiology of HIV Infection and Tuberculosis in Northern Thailand
P. Siriarayapon (2002)
10.1093/OXFORDJOURNALS.AJE.A121593
The prognosis of a positive tuberculin reaction in childhood and adolescence.
G. Comstock (1974)
The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia.
A. Elliott (1993)
10.1001/JAMA.1972.03200110051009
Isoniazid toxicity. A prospective study in secondary chemoprophylaxis.
C. B. Byrd (1972)
10.1097/00002030-200401020-00010
Decline in HIV infectivity following the introduction of highly active antiretroviral therapy
T. Porco (2004)
10.1016/S1473-3099(03)00609-1
Clinical diagnosis of smear-negative pulmonary tuberculosis in low-income countries: the current evidence.
K. Siddiqi (2003)
Mycobacterial disease in South African gold miners in the era of HIV infection.
G. Churchyard (1999)
10.1016/S0035-9203(98)90766-0
Anti-tuberculosis drug resistance in the world: The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Geneva: World Health Organization, 1997. 228pp. Price Sw. fr 25/US$22.50 (in developing countries Sw. fir 17.50). (Reference WHO/TB/97.229)
D. Wilkinson (1998)
10.7326/0003-4819-81-2-200
The effect of isoniazid on transaminase levels.
W. Bailey (1974)
10.1097/QAI.0b013e31818455d2
A Pilot Study of Food Supplementation to Improve Adherence to Antiretroviral Therapy Among Food-Insecure Adults in Lusaka, Zambia
R. Cantrell (2008)
Accuracy of routine diagnosis of pulmonary tuberculosis in an area of high HIV prevalence.
L. Apers (2004)
Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.
M. Espinal (2001)
10.1080/09540120020018161
Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA
D. Murphy (2001)
10.1086/521114
Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care.
M. Bedelu (2007)
10.1016/S0035-9203(97)90262-5
Screening pulmonary tuberculosis suspects in Malawi: testing different strategies.
A. Harries (1997)
10.1542/peds.2005-0975
Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy for Pediatric HIV Infection
R. Hazra (2005)
Should tuberculosis (TB) clinics provide (or refer for) antiretroviral therapy
S Royce (2008)
Tuberculosis and the HIV epidemic: increasing annual risk of infection in Kenya
Ja Odhiambo (1986)
10.1111/j.1365-3156.2004.01259.x
Integrating tuberculosis and HIV care in the primary care setting in South Africa
D. Coetzee (2004)
10.1097/00005792-199507000-00005
Correlates of Hepatitis C Virus Infections among Injection Drug Users
D. Thomas (1995)
10.1001/jama.1991.03470110027006
Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons--Florida and New York, 1988-1991.
(1991)
The Adult/Adolescent Spectrum of HIV Disease Group. HIV associated TB in the era of HAART
JL Jones (2000)
10.1016/0140-6736(93)91817-6
Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection
J. Pape (1993)
10.1016/S0140-6736(01)06712-5
HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers
P. Sonnenberg (2001)
10.1590/S0042-96862002000600015
Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
A. Pablos-Mendez (2002)
10.1097/QAI.0b013e318186eb18
CD4+ T-Cell Count Monitoring Does Not Accurately Identify HIV-Infected Adults With Virologic Failure Receiving Antiretroviral Therapy
D. Moore (2008)
10.1097/00126334-200309011-00005
A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients*
J. O. Stern (2003)
Community viral load counts and new HIV-positive patients
K Manavi (2006)
10.1097/00126334-200406010-00007
Long-Term CD4+ T-Cell Response to Highly Active Antiretroviral Therapy According to Baseline CD4+ T-Cell Count
F. García (2004)
10.1097/00126334-200408010-00006
A Pilot Study of Once-Daily Antiretroviral Therapy Integrated With Tuberculosis Directly Observed Therapy in a Resource-Limited Setting
Christopher D. Jack (2004)
10.1097/01.AIDS.0000096903.73209.AC
Tuberculosis epidemics driven by HIV: is prevention better than cure?
C. Currie (2003)
Validating clinical and immunological definitions of antiretroviral treatment failure in Malawi
M Hosseinipour (2007)
The impact of HIV infection on recurrence of tuberculosis in South African gold miners.
K. F. Mallory (2000)
10.1086/420834
Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis.
A. Coutsoudis (2004)
10.1056/NEJMSA031667
Priorities for the treatment of latent tuberculosis infection in the United States.
C. Horsburgh (2004)
10.1097/QAI.0b013e31804d685b
CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater
L. Gras (2007)
10.1146/ANNUREV.MED.55.091902.103753
Clinical management of tuberculosis in the context of HIV infection.
B. D. de Jong (2004)
10.1002/14651858.CD001442.PUB2
Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS.
M. Haddad (2000)
10.1111/j.1468-1293.2006.00383.x
The impact of malnutrition on survival and the CD4 count response in HIV‐infected patients starting antiretroviral therapy
N. Paton (2006)
Strategies for reducing the burden of TB infection and disease in high HIV prevalence populations: modelling the impact of active case finding, antiretrovirals and preventive therapy
EL Corbett (2002)
10.1001/JAMA.1996.03540150031027
A multi-institutional outbreak of highly drug-resistant tuberculosis: epidemiology and clinical outcomes.
T. Frieden (1996)
10.1590/S0042-96862002000300008
Interventions to reduce tuberculosis mortality and transmission in low- and middle-income countries.
M. Borgdorff (2002)
10.1164/RCCM.200310-1380OC
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis.
E. Nuermberger (2004)
10.1002/hep.20777
HIV coinfection shortens the survival of patients with hepatitis C virus–related decompensated cirrhosis
Carla W Brady (2005)
10.1164/AJRCCM.164.1.2101133
Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy.
W. Burman (2001)
Impact of HIV infection on rates of recurrence after treatment for tuberculosis in South African gold miners
KM Mallory (2000)
10.1164/RCCM.200410-1342OC
Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan.
C. Seyler (2005)
10.1097/QAD.0b013e328311ac4e
Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil
J. Golub (2008)
WHO public health approach to ART against HIV in resource-limited settings
C Gilks (2006)
10.1097/QAD.0b013e3282f09876
Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa
R. Moh (2007)
10.1164/AJRCCM.157.3.9708002
The host immune response to tuberculosis.
N. Schluger (1998)
10.1164/RCCM.200404-478OC
Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months.
D. Menzies (2004)
Risk factors for active tuberculosis following antiretroviral treatment initiation in Abidjan
C Seyler (2005)
48 week virological response to a triple nucleoside/nucleotide analogue regimen in adults with HIV infection in Africa within the DART trial.
P. Kaleebu (2005)
Impact of human immunodeficiency virus type-1 infection on the initial bacteriologic and radiographic manifestations of pulmonary tuberculosis in Uganda. Makerere University-Case Western Reserve University Research Collaboration.
J. Johnson (1998)
10.1086/524686
Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults.
D. Dunn (2008)
10.1001/JAMA.1979.03290380015017
Toxic effects of isoniazid in tuberculosis chemoprophylaxis. Role of biochemical monitoring in 1,000 patients.
R. B. Byrd (1979)
Can we get more HIV-positive tuberculosis patients on antiretroviral treatment in a rural district of Malawi?
R. Zachariah (2005)
HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult/Adolescent Spectrum of HIV Disease Group.
J. Jones (2000)
10.1001/JAMA.286.20.2560
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.
A. Phillips (2001)
10.7326/0003-4819-138-8-200304150-00007
Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata
F. Palella (2003)
10.1001/ARCHINTE.1996.00440070145017
Isoniazid preventive therapy.
S. Salpeter (1996)
Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana.
T. Kenyon (1999)
10.1016/S0140-6736(07)60948-9
Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study
A. Mocroft (2007)
10.1097/00002030-200105250-00006
When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study
A. C. Lepri (2001)
CD4R count and risk of non-AIDS diseases following initial treatment for HIV infection
JV Baker (2008)
10.1164/RCCM.2504003
The sound of one hand clapping: tuberculosis and antiretroviral therapy in Africa.
K. D. De Cock (2005)
Decreased bone mineral density with off-label use of tenofovir in HIV-infected children and adolescents
J Purdy (2008)
10.1097/00002030-200101260-00011
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults
M. Quigley (2001)
Transmission of Mycobacterium tuberculosis associated with failed completion of treatment for latent tuberculosis infection--Chickasaw County, Mississippi, June 1999-March 2002.
T. Chamblee (2003)
10.1097/00006254-200103000-00010
Trial of Shortened Zidovudine Regimens to Prevent Mother-to-Child Transmission of Human Immunodeficiency Virus Type 1
M. Lallemant (2001)
10.1093/HEAPOL/CZI013
Evaluation of a home-based voluntary counselling and testing intervention in rural Uganda.
B. Wolff (2005)
10.1590/S0042-96862002000600006
Low access to a highly effective therapy: a challenge for international tuberculosis control.
C. Dye (2002)
Tuberculosis bacteriology--priorities and indications in high prevalence countries: position of the technical staff of the Tuberculosis Division of the International Union Against Tuberculosis and Lung Disease.
A. Deun (2005)
10.1016/S0140-6736(02)11913-1
HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)
C. Thio (2002)
Interim policy on collaborative TB / HIV activities.
H. Getahun (2004)
10.1164/RCCM.200405-590OC
Human immunodeficiency virus and the prevalence of undiagnosed tuberculosis in African gold miners.
E. Corbett (2004)
10.2105/AJPH.92.3.388
Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco.
M. Katz (2002)
10.1007/s11606-007-0171-y
Adherence to Antiretroviral Therapy Assessed by Unannounced Pill Counts Conducted by Telephone
S. Kalichman (2007)
10.1016/S0140-6736(95)90519-7
Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire
A. Ackah (1995)
How well have 2006 WHO guidelines on cotrimoxazole prophylaxis (CTXp) been incorporated into national guidelines in resource-limited settings (RLS)
P Gavrilidis G Easterbrook (2006)
10.1097/00002030-200111090-00008
Chemoprophylaxis for tuberculosis and survival of HIV-infected patients in Brazil
A. M. de Pinho (2001)
10.1016/S1473-3099(05)70140-7
Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals.
S. Lawn (2005)
Global tuberculosis control: surveillance planning financing. WHO report 2008.
C. Dye (2003)
10.1111/j.1360-0443.2008.02323.x
The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
P. Roux (2008)
Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection.
De Cock Km (1999)
Tuberculosis control in the era of the HIV epidemic: risk of tuberculosis infection in Tanzania, 1983-1998.
(2001)
10.1053/JHEP.2002.30319
Hepatotoxicity associated with nevirapine or efavirenz‐containing antiretroviral therapy: Role of hepatitis C and B infections
M. Sulkowski (2002)
10.1093/IJE/DYM104
Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.
E. Arrivé (2007)
10.1016/S0140-6736(02)08904-3
Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study
M. Badri (2002)
10.1097/OLQ.0b013e31816b475a
HIV Risk Factors Reported by Two Samples of Male Bathhouse Attendees in Los Angeles, California, 2001–2002
T. Bingham (2008)
10.1002/hep.22462
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand
G. Matthews. (2008)
10.1001/ARCHINTE.1997.00440240073011
Anonymous HIV testing using home collection and telemedicine counseling. A multicenter evaluation.
A. Frank (1997)
10.1136/bmj.317.7159.625
Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials
D. Wilkinson (1998)
10.1093/CLINIDS/24.6.1264
Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin.
R. Ridzon (1997)
10.1001/ARCHINTE.163.9.1009
The growing burden of tuberculosis: global trends and interactions with the HIV epidemic.
E. Corbett (2003)
Health sector reform and tuberculosis control: the case of Zambia.
M. Bosman (2000)
10.1016/S0022-3476(76)80949-3
Isoniazid hepatitis in adolescents.
I. Litt (1976)
10.1086/313843
Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.
J. Kaplan (2000)
10.1016/J.IJID.2006.11.003
Sensitivity and specificity of using CD4+ measurement and clinical evaluation to determine antiretroviral treatment failure in Thailand.
R. Chaiwarith (2007)
A comprehensive comparison of Ziehl-Neelsen and fluorescence microscopy for the diagnosis of tuberculosis in a resource-poor urban setting.
L. Kivihya-Ndugga (2003)
10.1179/107735207800244910
A Successful Workplace Program for Voluntary Counseling and Testing and Treatment of HIV/AIDS at Heineken, Rwanda
F. Feeley (2007)
Long-term outcome in patients registered with tuberculosis in Zomba, Malawi: mortality at 7 years according to initial HIV status and type of TB.
C. Kang'ombe (2004)
10.1001/ARCHINTE.1997.00440360155017
Isoniazid preventive therapy in human immunodeficiency virus-infected persons. Long-term effect on development of tuberculosis and survival.
S. Moreno (1997)
10.1086/503905
Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups.
G. Lucas (2006)
10.1371/journal.pmed.0050109
Pharmacy Refill Adherence Compared with CD4 Count Changes for Monitoring HIV-Infected Adults on Antiretroviral Therapy
G. Bisson (2008)
10.1164/AJRCCM.154.5.8912767
Rifampin preventive therapy for tuberculosis in Boston's homeless.
A. Polesky (1996)
10.1086/422724
Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?
F. Gordin (2004)
Preventive therapy against tuberculosis in people living with HIV.
(1999)
10.1016/S0140-6736(04)17141-9
Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial
A. Jindani (2004)
10.1089/APC.2006.0037
Establishing CD4 thresholds for highly active antiretroviral therapy initiation in a cohort of HIV-infected adult Chinese in Hong Kong.
K. Wong (2007)
10.1016/0962-8479(95)90572-3
Impact of the HIV epidemic on trends in tuberculosis in Abidjan, Côte d'Ivoire.
S. B. Richards (1995)
10.1016/S0140-6736(04)17225-5
Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda
J. Mermin (2004)
10.1056/NEJM199201233260404
An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms.
C. Daley (1992)
Human resources for control of tuberculosis and HIV-associated tuberculosis.
A. Harries (2005)
10.1097/01.ogx.0000265886.39897.cb
Response to antiretroviral therapy after a single, peripartum dose of nevirapine.
S. Lockman (2007)
10.1097/00002030-200201040-00010
Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy
G. Dean (2002)
Voluntary counselling, HIV testing and adjunctive cotrimoxazole are associated with improved TB treatment outcomes under routine conditions in Thyolo District, Malawi.
R. Chimzizi (2004)
10.1086/429912
Chronic cough in primary health care attendees, Harare, Zimbabwe: diagnosis and impact of HIV infection.
S. Munyati (2005)
10.1164/ARRD.1962.85.4.490
Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts.
S. Ferebee (1962)
10.1086/429825
High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania.
L. Mtei (2005)
10.1086/426827
How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners.
P. Sonnenberg (2005)
10.1002/HEP.510300409
Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients
Y. Benhamou (1999)
A comprehensive study of the efficiency of the routine pulmonary tuberculosis diagnostic process in Nairobi.
M. van Cleeff (2003)
10.3201/eid1009.040349
New Measurable Indicator for Tuberculosis Case Detection
M. Borgdorff (2004)
10.1097/01.AIDS.0000131337.22924.0D
Trends in tuberculosis and the influence of HIV infection in northern Malawi, 1988-2001.
M. Borgdorff (2004)
10.1001/JAMA.286.2.171
Prevalence and predictive value of intermittent viremia with combination hiv therapy.
D. Havlir (2001)
10.1016/S0140-6736(08)61311-2
Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review
Bradley M. Mathers (2008)
Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.
C. Orrell (2007)
10.1001/ARCHPEDI.157.3.249
Barriers to HAART adherence among human immunodeficiency virus-infected adolescents.
D. Murphy (2003)
10.1016/S0163-4453(98)90561-8
Chronic diarrhoea among HIV-infected adult patients in Nairobi, Kenya
C. Mwachari (1998)
10.1097/01.qai.0000122708.59121.03
Body Mass Index at Time of HIV Diagnosis: A Strong and Independent Predictor of Survival
M. V. D. van der Sande (2004)
10.1097/00002030-200012010-00016
HIV infection and silicosis: the impact of two potent risk factors on the incidence of mycobacterial disease in South African miners
E. Corbett (2000)
10.1097/00002030-199903110-00009
Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials.
H. Bucher (1999)
10.1086/422601
Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan.
C. Fang (2004)
10.1007/s10461-008-9489-7
Adherence to Antiretroviral Therapy Among HIV-Infected Drug Users: A Meta-Analysis
M. Malta (2008)
10.1097/01.inf.0000250625.80340.48
Patient, Caregiver and Regimen Characteristics Associated With Adherence to Highly Active Antiretroviral Therapy Among HIV-Infected Children and Adolescents
S. Martin (2007)
10.1136/sti.2006.021097
Improved plausibility bounds about the 2005 HIV and AIDS estimates
M. Morgan (2006)
HIV associated TB in the era of HAART
JL Jones (2000)
10.1097/01.AIDS.0000131336.15301.06
Trends in tuberculosis and the influence of HIV infection in northern Malawi, 1988–2001
J. Glynn (2004)
10.1128/JVI.74.8.3579-3585.2000
The M184V Mutation in the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 Impairs Rescue of Chain-Terminated DNA Synthesis
M. Götte (2000)
10.1086/514084
Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires.
V. Ritacco (1997)
10.1097/00042560-200104010-00006
Changing Clinical Presentation and Survival in HIV‐Associated Tuberculosis After Highly Active Antiretroviral Therapy
E. Girardi (2001)
Are smear-positive pulmonary tuberculosis patients a 'sentinel' population for the HIV epidemic in Cameroon?
J. Noeske (2004)
10.1097/00042560-200007010-00003
Mortality for liver disease in patients with HIV infection: a cohort study.
M. Puoti (2000)
10.1056/NEJM199709183371201
A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunodeficiency virus. Uganda-Case Western Reserve University Research Collaboration.
C. Whalen (1997)
Prevalence of HIV and other sexually transmitted infections among female sex workers in Kisumu, western Kenya
HM Vandenhoudt (1997)
Will DOTS do it? A reappraisal of tuberculosis control in countries with high rates of HIV infection.
K. D. De Cock (1999)
Random - ised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV - 1 infection
NA Halsey (1998)
10.1126/SCIENCE.1069771
Resources Required for Global Tuberculosis Control
K. Floyd (2002)
10.1378/CHEST.99.2.465
Toxic hepatitis with isoniazid and rifampin. A meta-analysis.
M. Steele (1991)
Antiretroviral therapy for TB control in the era of HIV/AIDS
BG Williams (2003)
10.1016/S0140-6736(05)66518-X
Fair process in patient selection for antiretroviral treatment in WHO's goal of 3 by 5
N. Daniels (2005)
10.1001/JAMA.281.11.1014
Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.
C. Nolan (1999)
10.1097/00002030-200405210-00009
Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-up guidelines
M. Badri (2004)
10.1097/QAD.0b013e328216f441
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil
J. Golub (2007)
Implementing joint TB and HIV interventions in a rural district of Malawi: is there a role for an international non-governmental organisation?
R. Zachariah (2004)
10.1097/00002030-199818000-00014
Twice weekly tuberculosis preventive therapy in HIV infection in Zambia
A. Mwinga (1998)
10.1164/ARRD.1978.117.6.991
Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study.
D. E. Kopanoff (1978)
10.1300/J465v27n04_07
HIV Incidence, Retention, and Changes of High-Risk Behaviors Among Rural Injection Drug Users in Guangxi, China
L. Wei (2006)
10.1016/S0140-6736(02)09411-4
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
M. Egger (2002)
10.1086/516297
Fatal Mycobacterium tuberculosis bloodstream infections in febrile hospitalized adults in Dar es Salaam, Tanzania.
L. Archibald (1998)
10.1016/S1054-139X(03)00160-5
Case finding for HIV-positive youth: a special type of hidden population.
D. Bell (2003)
Recent studies in the epidemiology of tuberculosis, based on the risk of being infected with tubercle bacilli.
I. Sutherland (1976)
10.1128/AAC.48.5.1553-1560.2004
Pharmacokinetics of Adjusted-Dose Lopinavir-Ritonavir Combined with Rifampin in Healthy Volunteers
C. L. la Porte (2004)
Evaluation of World Health Organization criteria for antiretroviral treatment failure in resource-limited settings
P Mee (2006)
10.2105/AJPH.89.7.1078
Tuberculosis and the HIV epidemic: increasing annual risk of tuberculous infection in Kenya, 1986-1996.
J. Odhiambo (1999)
Tanzanian National tuberculin survey, 4th round results of interim analysis of 12 regions
SM Egwaga (2003)
10.1097/00002030-199309000-00014
A clinical and pathological comparison of the WHO and CDC case definitions for AIDS in Kinshasa, Zaïre: is passive surveillance valid?
A. Nelson (1993)
10.1086/345906
Isoniazid hepatotoxicity among drug users: the role of hepatitis C.
A. Fernández-Villar (2003)
10.1016/0962-8479(95)90548-0
The International Union Against Tuberculosis and Lung Disease model National Tuberculosis Programmes.
D. Enarson (1995)
Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach
J. Curran (2005)
10.1097/QAD.0b013e32830e4cd8
Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa
P. Mee (2008)
10.1056/NEJM200104263441706
Global trends in resistance to antituberculosis drugs.
M. Espinal (2001)
10.1097/00126334-200303010-00010
Short-term CD4 cell response after highly active antiretroviral therapy initiated at different times from seroconversion in 1,500 seroconverters.
A. Babiker (2003)
10.1590/S0042-96862004000500009
Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Karonga District, Malawi.
F. Mwaungulu (2004)
HIV infection and the duration and control of prevalent tuberculosis disease in Harare, Zimbabwe
Elizabeth L. Corbett (2005)
10.1097/01.aids.0000163936.99401.fe
Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort
D. Konopnicki (2005)
10.1086/378519
Stable incidence rates of tuberculosis (TB) among human immunodeficiency virus (HIV)-negative South African gold miners during a decade of epidemic HIV-associated TB.
E. Corbett (2003)
10.1016/S0002-9343(01)00695-7
A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users.
R. Chaisson (2001)
10.1097/00042560-200109010-00008
Trust and the Acceptance of and Adherence to Antiretroviral Therapy
F. Altice (2001)
10.1097/00002030-200305020-00015
Voluntary counselling, HIV testing and adjunctive cotrimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi
R. Zachariah (2003)
10.1016/S0140-6736(03)14745-9
Value of chest radiography in a tuberculosis prevention programme for HIV-infected people, Botswana
B. Mosimaneotsile (2003)
10.1086/380794
Pharmacokinetic interaction between rifampin and the combination of indinavir and low-dose ritonavir in HIV-infected patients.
U. Justesen (2004)
10.1001/ARCHINTE.162.1.97
Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy.
E. Navas (2002)
10.1097/00002030-200009080-00015
Impact of combination antiretroviral therapy on the risk of tuberculosis among persons with HIV infection
E. Girardi (2000)
10.1371/journal.pmed.0030438
Adherence to HAART: A Systematic Review of Developed and Developing Nation Patient-Reported Barriers and Facilitators
E. Mills (2006)
10.1016/S0140-6736(04)17140-7
Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis
Marie‐Louise Newell (2004)
10.1111/j.1365-3156.2008.02148.x
Individual, household and community factors associated with HIV test refusal in rural Malawi
K. Kranzer (2008)
10.1016/S0035-9203(98)90727-1
Prevalence of tuberculosis in TB suspects with short duration of cough.
H. Banda (1998)
10.1086/592115
Rate of comorbidities not related to HIV infection or AIDS among HIV-infected patients, by CD4 cell count and HAART use status.
R. Moore (2008)
Natural history and spectrum of disease in adults with HIV/AIDS in Africa.
A. Grant (1997)
10.1097/00002030-200008180-00018
Home collection for frequent HIV testing: acceptability of oral fluids, dried blood spots and telephone results
F. Spielberg (2000)
Manage - ment of persons exposed to multidrug - resistant tuberculosis
R Ridzon (1992)
36 World Health Organisation, UNAIDS. Preventive therapy against tuberculosis in people living with HIV
(1999)
10.1097/00019048-200112000-00012
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.
J. Keane (2001)
10.1086/586713
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.
S. Emery (2008)
10.1097/00042560-200005010-00004
Autopsy Study of HIV‐1‐Positive and HIV‐1‐Negative Adult Medical Patients in Nairobi, Kenya
F. Rana (2000)
10.1086/375220
Effects of human immunodeficiency virus infection on recurrence of tuberculosis after rifampin-based treatment: an analytical review.
E. Korenromp (2003)
10.1016/S0140-6736(02)09337-6
Shadow on the continent: public health and HIV/AIDS in Africa in the 21st century
K. M. Cock (2002)
A clinical and pathological comparison of the WHO and CDC case definitions for AIDS in Kinshasa, Zaire: is passive surveillance valid? AIDS
AM Nelson (1993)
Joint TB and HIV interventions saved the lives of more than 400 000 people in 2011 alone (eight times
Fig (2005)
Population based screening for active tuberculosis in a community with endemic TB. 33rd World Conference on Lung Health
Gj Churchyard (2002)
10.1001/JAMA.282.7.677
Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country
C. Dye (1999)
10.1164/ARRD.1969.100.6.773
Isoniazid prophylaxis in Alaskan Boarding schools. A comparison of two doses.
G. Comstock (1969)
10.1097/QAI.0b013e31816e395c
Prevention of Mother-to-Child Transmission of HIV-1 Through Breast-Feeding by Treating Infants Prophylactically With Lamivudine in Dar es Salaam, Tanzania: The Mitra Study
C. Kilewo (2008)
10.1111/j.1468-1293.2005.00271.x
Changing mortality rates and causes of death for HIV‐infected individuals living in Southern Alberta, Canada from 1984 to 2003
H. Krentz (2005)
10.1164/AJRCCM.155.5.9154885
Rifampin preventive therapy for tuberculosis infection: experience with 157 adolescents.
M. Villarino (1997)
Population based screening for active tuberculosis in a community with endemic TB
GJ Churchyard (2002)
10.1016/S0140-6736(00)02089-4
Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya
J.A.G. Scott (2000)
Chronic cough in primary health care attendees, Harare, Zimbabwe: diagnosis and impact of human immunodeficiency virus
SS Munyati (2005)
10.1097/01.qai.0000179455.01068.ab
Removing Barriers to Knowing HIV Status: Same-Day Mobile HIV Testing in Zimbabwe
S. Morin (2006)
10.1097/00007435-200305000-00010
Use-Effectiveness of the Female Versus Male Condom in Preventing Sexually Transmitted Disease in Women
P. French (2003)
10.1007/s10198-005-0327-9
Comparing costs and effectiveness of different starting points for highly active antiretroviral therapy in HIV-positive patients
M. Merito (2005)
10.1016/S0140-6736(05)67062-6
Antituberculosis drug resistance and anonymous HIV surveillance in tuberculosis patients in Botswana, 2002
L. Nelson (2005)
10.1128/JCM.39.3.1042-1047.2001
Molecular and Conventional Epidemiology ofMycobacterium tuberculosis in Botswana: a Population-Based Prospective Study of 301 Pulmonary Tuberculosis Patients
S. Lockman (2001)
10.1097/01.aids.0000216371.76689.63
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures
M. Johnson (2006)
10.1378/CHEST.68.2.181
Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy.
J. R. Mitchell (1975)
HIV infection and the duration and control of prevalent tuberculosis disease in Harare
El Corbett (2005)
10.1016/0962-8479(94)90036-1
Tuberculosis preventive therapy in HIV-infected individuals.
(1994)
10.1016/J.TRSTMH.2004.05.002
Monitoring the response to antiretroviral therapy in resource-poor settings: the Malawi model.
A. Harries (2004)
10.1001/jama.1992.03490120095035
Tuberculosis and HIV infection in sub-Saharan Africa.
K. D. De Cock (1992)
10.1164/RCCM.200407-885OC
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis.
E. Nuermberger (2004)
Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis.
(1982)
Tuberculosis and the HIV epidemic: increasing annual risk of infection in Kenya, 1986–1996
JA Odhiambo (1999)
10.1097/00002030-200309260-00007
Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy?
G. Churchyard (2003)
10.1016/0962-8479(95)90011-X
Radiologic manifestations of pulmonary tuberculosis in HIV-1 and HIV-2-infected patients in Abidjan, Côte d'Ivoire.
L. Abouya (1995)
10.7326/0003-4819-137-8-200210150-00007
Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Multicenter Clinical Trial
R. Jasmer (2002)
10.1108/09526869810216043
Block appointments in an overloaded South African health centre: quantitative and qualitative evaluation.
H. Mahomed (1998)
10.1097/00002030-200207050-00009
Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/l
M. Opravil (2002)



This paper is referenced by
10.2174/1874279301307010001
Benchmarking to Assess Potential Under-Diagnosis of Smear-Negative and Extrapulmonary Tuberculosis. A Case Study from Mozambique
M. Brouwer (2013)
10.1016/j.tube.2008.05.004
Pulmonary tuberculosis: virulence of Mycobacterium africanum and relevance in HIV co-infection.
C. Meyer (2008)
Feasibility of routine HIV testing among TB patients through a voluntary counselling and testing centre.
B. Thomas (2007)
10.1007/978-0-387-72711-0_3
Future of HIV/AIDS Care in Low- and Middle- Income Countries
C. Hoffmann (2008)
10.1111/J.1574-6968.2006.00356.X
Use of a codon alteration strategy in a novel approach to cloning the Mycobacterium tuberculosis diaminopimelic acid epimerase.
V. Usha (2006)
10.1007/978-3-030-18690-6_15
Bovine Tuberculosis in Ghana
D. Yeboah-Manu (2019)
10.1111/tbed.12764
Tuberculosis serosurveillance and management practices of captive African elephants (Loxodonta africana) in the Kavango-Zambezi Transfrontier Conservation Area.
L. E. Rosen (2018)
10.1007/s11239-020-02211-7
Global epidemiology of venous thromboembolism in people with active tuberculosis: a systematic review and meta-analysis
C. Danwang (2020)
10.2989/16085906.2012.698076
Perceptions of HIV, AIDS and tuberculosis among patients on antiretroviral therapy in Bulawayo, Zimbabwe: implications for the provision of HIV and TB care services
A. Roedlach (2012)
Pulmonary Tuberculosis as a comorbid condtion in HIV positive adults and its effects on Neuro-cognitive function in Zambia
J. Chinyama (2014)
10.1097/01.AIDS.0000232241.13168.5C
Tuberculosis: the elephant in the AIDS clinic?
B. Marston (2006)
10.3389/fmicb.2014.00272
CD8 T-cell-mediated protection against liver-stage malaria: lessons from a mouse model
Natalija Van Braeckel-Budimir (2014)
10.1146/annurev-publhealth-031912-114431
Prospects for tuberculosis elimination.
C. Dye (2013)
10.1186/1471-2334-10-344
Blood cultures for the diagnosis of multidrug-resistant and extensively drug-resistant tuberculosis among HIV-infected patients from rural South Africa: a cross-sectional study
S. Heysell (2010)
PEPFAR public health evaluation -- care and support. Phase 2 Uganda.
Simms (2010)
10.1016/j.ijid.2012.05.1026
Tuberculosis, incarceration, and HIV at a crossroads in Guyana.
Curtis La Fleur (2012)
10.5897/AJMR12.1209
Advances in tuberculosis
A. Aseffa (2013)
10.1097/QAI.0b013e3181aa8a3d
Optimal versus suboptimal treatment for HIV-infected pregnant women and HIV-exposed infants in clinical research studies.
A. J. Ammann (2009)
10.1086/651497
Integration of tuberculosis and HIV services in sub-Saharan Africa: lessons learned.
A. Howard (2010)
Clinical and pathological characteristics of the Uganda genotype of Mycobacterium tuberculosis
D. Wamala (2016)
10.1097/QAD.0b013e3282f7cb4b
Impact of HIV on novel therapies for tuberculosis control
M. S. Sánchez (2008)
10.1016/B978-0-443-06668-9.50041-7
Tuberculosis and Atypical Mycobacterial Infections
J. L. Johnson (2006)
10.1111/j.1471-0528.2010.02771.x
Tuberculosis in pregnancy
CN Mnyani (2011)
10.35366/57351
Cavernas pulmonares gigantes cicatrizadas, no colapsadas que simulan bulas de enfisema
Edelberto Fuentes-Valdés (2015)
The Presence of Tuberculosis at the Initiation of Antiretroviral Therapy Predicts Retention in Care: A Retrospective Review of Patients on ART in Nigeria
Joseph E Enegela (2015)
10.1016/j.trstmh.2011.10.015
Loss to follow up from isoniazid preventive therapy among adults attending HIV voluntary counseling and testing sites in Uganda.
P. M. Namuwenge (2012)
[Change in the survival of Cuban AIDS patients with tuberculosis in the Highly Active Antiretroviral Therapy (HAART) era].
A. Reyes-Corcho (2008)
Tuberculosis among HIV-positive patients at Butajira Hospital , South-Central Ethiopia
Seada Mohammed (2015)
10.1111/tmi.12618
The impact of alcohol consumption on African people in 2012: an analysis of burden of disease
Carina Ferreira-Borges (2016)
10.1128/9781555817138.CH11
Tuberculosis—a World Health Organization Perspective
M. Espinal (2011)
10.2174/156720112803529819
Permeation of PLGA nanoparticles across different in vitro models.
L. Nkabinde (2012)
10.1007/978-1-4419-6064-1_9
Mathematical modelling of the epidemiology of tuberculosis.
P. White (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar